In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.
A ‘Few Bad Apple’ Docs Spread COVID Misinformation on Social Media
Physician propagation of COVID-19 misinformation on social media — primarily discouraging people from getting the COVID vaccine — was limited but still potentially harmful, a
August 16, 2023